Improving haemophilia patient care through sharing best practice

European Journal of Haematology

Volumn 95, Issue , 2015, Pages 1-8

  de Moerloose, Philippe ^a   Arnberg, Daniel ^b   O'Mahony, Brian ^c   Colvin, Brian ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SCISS AB   (Sweden)

^c European Haemophilia Consortium   (Belgium)

^d PFIZER INC   (United States)

Author keywords

Advocacy; Best practice; Health technology assessment; Outcome data; Patient organisation

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR CONCENTRATE;

ACT; ARTICLE; BELGIUM; BIOMEDICAL TECHNOLOGY ASSESSMENT; DATA SHARING; EUROPE; HEALTH CARE ORGANIZATION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFORMATION PROCESSING; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SOCIETY; PATIENT ADVOCACY; PATIENT CARE; PATIENT PARTICIPATION; PHARMACEUTICAL BENEFITS ACT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SUBSTITUTION THERAPY; SWEDEN; SWITZERLAND; SYMPOSIUM; SYSTEMATIC REVIEW (TOPIC); VIRUS TRANSMISSION; VON WILLEBRAND DISEASE; CLINICAL DECISION MAKING; DISEASE MANAGEMENT; INFORMATION DISSEMINATION; PROCEDURES; STANDARDS; TOTAL QUALITY MANAGEMENT;

CLINICAL DECISION-MAKING; DISEASE MANAGEMENT; EUROPE; HEMOPHILIA A; HUMANS; INFORMATION DISSEMINATION; PATIENT CARE; QUALITY IMPROVEMENT;

EID: 84940909529     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12630     Document Type: Article

References (29)

1. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013;19:e239-47.
2. Prevention and Control of Haemophilia. Memorandum from a joint WHO/WFH meeting. Bull World Health Organ 1991;69:17-26.
3. Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peak I, Rickard K, Seremetis S, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701.
4. Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, Thomas A, Ingerslev J; Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008;14:361-74.
5. de Moerloose P, Fischer K, Lambert T, Windyga J, Batorova A, Lavigne-Lissalde G, Rocino A, Astermark J, Hermans C. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012;18:319-25.
6. Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 2014;20:322-5.
7. Fischer K, Hermans C; European Haemophilia Therapy Standardisation Board. The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013;19:35-43.
8. Schramm W, Gringeri A, Ljung R, et al.; ESCHQOL Study Group. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012;18:729-37.
9. Ingerslev J, Lethagen S, Hvitfeldt Poulsen L, Sørensen B, Lopatina E, Tentsova I, Yastrubinetskaya O, Plyushch OP. Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients. Haemophilia 2014;20:58-64.
10. EU Directive 2011/24/EU On the application of patients' rights in cross-border healthcare. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF (Accessed January 2015).
11. Feldman BM, Berger K, Bohn E, et al. Haemophilia prophylaxis: how can we justify the costs? Haemophilia 2012;18:680-4.
12. Farrugia A, O'Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia 2012;18:152-7.
13. Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013;19:660-7.
14. Giangrande P, Calizzani G, Menichini I, Candura F, Mannucci P, Makris M. The European standards of Haemophilia Centres. Blood Transf 2014;12(Suppl 3):s525-30.
15. Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmström M, Ljungberg B, Norlund A, Palmblad J, Petrini P, Stigendal L, Säwe J. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012;18:158-65.
16. Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, van den Berg HM, Berntorp E. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013;122:1129-36.
17. Coppola A, Franchini M. Target of prophylaxis in severe haemophilia: more than factor levels. Blood Transfus 2013;11:327-9.
18. Act (2002:160) on Pharmaceutical Benefits, etc. Issued April 2002. Available at: www.tlv.se/Upload/English/ENG-act-2002-160.pdf (Accessed December 2014).
19. Act (2002:687) om läkemedelsförmåner m.m. www.riksdagen.se/sv/Dokument-Lagar/Lagar/Svenskforfattningssamling/Forordning-2002687-om-lakem_sfs-2002-687/?bet=2002:687 (Accessed December 2014).
20. TLV. Handbook - reviewing the reimbursement status of pharmaceuticals. www.tlv.se/Upload/English/ENG-handbook.pdf (Accessed December 2014).
21. Treatment of Hemophilia A and B and von Willebrand Disease, (No 208E) by SBU. www.sbu.se/en/Published/Yellow/Treatment-of-Hemophilia-A-and-B-and-von-Willebrand-disease/ (Accessed December 2014).
22. Swedish Council on Health Technology Assessment. Treatment of Hemophilia A and B and von Willebrand Disease. A systematic review. May 2011. www.sbu.se/upload/publikationer/content0/1/blodarsjuka/treatment%20of%20hemophilia%20a%20and%20b.pdf (Accessed December 2014).
23. Srivastava A. Haemophilia care - beyond the treatment guidelines. Haemophilia 2014;20(Suppl.4):4-10.
24. O'Mahony B, et al. An Introduction to Key Concepts in Health Economics for Haemophilia Organisations. Montreal, Canada: WFH, 2010.
25. Irish Haemophilia Society. Data on file.
26. Noone D, et al. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophilia 2011;17:e842-3.
27. Noone D, et al. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013;19:44-50.
28. European Haemophilia Consortium. EHC Newsletter December 2013. www.ehc.eu/fileadmin/newsletter/2013/EHC_Newsletter_December_2013.pdf (Accessed November 2014).
29. Farrugia A, et al. Treatment for life for severe haemophilia A - a cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013;19:e228-38.